FDA Approval for Pediatric Use
Neupogen (filgrastim) is FDA-approved for children starting at 0 months old in specific cases, including reducing infection risk after chemotherapy for acute myeloid leukemia (AML) or after bone marrow transplant. Approval covers neonates, infants, and older kids when benefits outweigh risks.[1][2]
Common Side Effects in Children
Kids on Neupogen often experience bone pain (up to 30% in studies), fever, and rash. These are usually mild to moderate and managed with pain relievers. Splenic rupture, a rare but serious risk in adults, has not been widely reported in pediatric trials but requires monitoring via ultrasound if abdominal pain occurs.[1][3]
Serious Risks and Warnings
Acute respiratory distress syndrome (ARDS) can happen, especially post-chemotherapy; stop treatment if lung issues arise. Allergic reactions, capillary leak syndrome, and potential tumor growth promotion in myeloid cancers are black-box warnings applying to all ages. Long-term effects on growth or fertility remain under study, with no definitive data showing harm.[2][4]
Safety in Clinical Studies
Pediatric trials (e.g., for AML induction chemo) showed Neupogen shortened neutropenia duration by 3-5 days without increasing infection rates or mortality compared to placebo. Preterm neonates tolerated it well for sepsis prevention, though some studies noted transient thrombocytopenia. No unique pediatric contraindications beyond adult ones.[3][5]
Differences from Adult Use
Dosing is weight-based (5 mcg/kg/day subcutaneously), and kids clear the drug faster, often needing higher or more frequent doses. Safety profile mirrors adults, but monitoring for spleen enlargement is emphasized more in young patients.[1][2]
Sources
[1]: Neupogen Prescribing Information (FDA)
[2]: FDA Label for Pediatric Indications
[3]: Pediatric Oncology Study (NEJM)
[4]: Drugs.com Neupogen Side Effects
[5]: Cochrane Review on Filgrastim in Neonates